News
CINGW
0.0303
-7.34%
-0.0024
Weekly Report: what happened at CINGW last week (0323-0327)?
Weekly Report · 2d ago
CINGULATE INC: FILES PROSPECTUS SUPPLEMENT RELATES TO ISSUANCE AND SALE OF COMMON STOCK OF UP TO $100 MLN FROM TIME TO TIME
Reuters · 03/24 21:20
Cingulate held special stockholder meeting to approve issuance proposal
Reuters · 03/24 21:15
Weekly Report: what happened at CINGW last week (0316-0320)?
Weekly Report · 03/23 09:18
CINGULATE INC - FILES TO OFFER AND RESALE OF UP TO 3.5 MLN SHARES BY LINCOLN PARK CAPITAL FUND - SEC FILING
Reuters · 03/20 10:03
ADHD drug developer Cingulate's Q4 net loss misses analyst expectations as G&A costs rise
Reuters · 03/18 12:10
Cingulate Q4 net loss was USD 6.27 million as G&A expenses rose 91% to USD 3.58 million
Reuters · 03/18 12:04
CINGULATE Q4 NET INCOME USD -6.3 MILLION VS. IBES ESTIMATE USD -4.52 MILLION
Reuters · 03/18 12:00
Weekly Report: what happened at CINGW last week (0309-0313)?
Weekly Report · 03/16 09:18
Weekly Report: what happened at CINGW last week (0302-0306)?
Weekly Report · 03/09 09:18
Weekly Report: what happened at CINGW last week (0223-0227)?
Weekly Report · 03/02 09:18
Weekly Report: what happened at CINGW last week (0216-0220)?
Weekly Report · 02/23 09:18
Cingulate Inc. Announces Special Meeting of Stockholders
Reuters · 02/18 21:06
Cingulate Raises $12 Million in Private Placement
Reuters · 02/17 13:00
Weekly Report: what happened at CINGW last week (0209-0213)?
Weekly Report · 02/16 09:18
Cingulate Inc. SVP and CFO Jennifer L. Callahan Reports Acquisition of Common Shares
Reuters · 02/11 00:00
Cingulate Inc. Director Peter J. Werth Reports Acquisition of Common Shares
Reuters · 02/11 00:00
Cingulate CEO Shane J. Schaffer Reports Acquisition of Common Shares
Reuters · 02/11 00:00
Weekly Report: what happened at CINGW last week (0202-0206)?
Weekly Report · 02/09 09:18
Cingulate Inc. Raises $6.5 Million in Private Placement of Unregistered Shares
Reuters · 02/06 21:13
More
Webull provides a variety of real-time CINGW stock news. You can receive the latest news about Cingulate through multiple platforms. This information may help you make smarter investment decisions.
About CINGW
Cingulate Inc. is a biopharmaceutical company. The Company is focused on the development, manufacturing, and commercialization of pharmaceutical products that utilize its precision timed release (PTR) drug delivery platform technology to create dosing schedules and drug release profiles. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD). The Company is in the development of two lead product candidates, such as CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine). The Company’s CTx-1301 and CTx-1302 are being developed for the treatment of ADHD in the three core patient segments: children (ages 6-12), adolescents (ages 13-17), and adults (ages18+). In addition, the Company has a third product to treat anxiety, CTx-2103, in a formulation stage. Its CTx-1301, CTx-1302 and CTx-2103 drug candidates contain three releases of active pharmaceutical ingredient combined into one small tablet dosage form.